<DOC>
	<DOCNO>NCT00619307</DOCNO>
	<brief_summary>To assess patient satisfaction respect incidence flu-like symptom ( FLS ) patient multiple sclerosis transition current Rebif ( subcutaneously inject interferon beta-1a , 44 mcg three-times-weekly ) new formulation Rebif ( RNF ) receive ibuprofen either prophylactically necessary ( PRN ) occurence flu-like symptom .</brief_summary>
	<brief_title>Transition Rebif New Formulation</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>Subject relapse form Multiple Sclerosis ( MS ) Expanded disability status scale ( EDSS ) score &lt; 5.5 study entry Subjects administer Rebif 44 mcg three time week least 6 month prior study enrolment Subject currently use Rebiject II use Rebiject II Rebif New Formulation injection Subject 18 60 year old inclusive Female subject must neither pregnant breastfeeding must lack childbearing potential , define either : postmenopausal surgically sterile , use highly effective method contraception . Subject willing follow study procedure Subject willing must present contraindication take ibuprofen 4 week study Subject give write informed consent Secondary Progressive Multiple Sclerosis without superimposed attack Use injectible medication week prior screening period , screen treatment period Subject receive MS therapy addition ( i.e . combination therapy ) Rebif within 3 month prior study enrolment time study protocol History chronic pain syndrome Subjects use investigational drug experimental procedure within 12 week visit Subject receive corticosteroid adrenocorticotrophic hormone ( ACTH ) within 30 day visit 1 Subject flulike symptom ( FLS ) associate cause ( i.e . current flu FLS relate Interferon week prior baseline ) Subject abnormal liver function , define total bilirubin &gt; 1.5 time upper limit normal , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2.5 time upper limit normal value . Subject inadequate bone marrow reserve , define total white blood cell count &lt; 3.0 x 109/L , platelet count &lt; 75 x 109/L , haemoglobin &lt; 100 g/L . Subject suffers active autoimmune disease MS Subject suffers major medical psychiatric illness Subject seizures history currently experience seizure adequately control antiepileptic Subject pregnant attempt conceive Visual physical impairment precludes completion diary questionnaires himself/herself Contraindication ibuprofen : know hypersensitivity active ingredient ibuprofen Known hypersensitivity nonsteroidal antiinflammatory drug lead asthmatic attack , gastric and/or intestinal ulcer , gastrointestinal bleeding , cerebrovascular bleed active bleeding , severe hepatic dysfunction , severe kidney dysfunction , severe cardiac insufficiency , systemic lupus erythematosus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>